Cooper Stock Price, News & Analysis

CooperCompanies (COO) reported strong Q1 2025 financial results with revenue increasing 4% year-over-year to $964.7 million. The company's two main segments showed growth: CooperVision revenue up 4% to $646.1 million and CooperSurgical revenue up 3% to $318.6 million.

Key financial metrics include:

• GAAP diluted EPS of $0.52, up $0.11 from last year
• Non-GAAP diluted EPS of $0.92, up $0.07
• Gross margin improved to 68% from 67%
• Operating margin increased to 19% from 16%
• Free cash flow of $101.2 million

The company updated its FY2025 guidance, projecting total revenue of $4,080 - $4,158 million (6-8% organic growth) and raised its non-GAAP diluted EPS guidance to $3.94 - $4.02.

CooperCompanies (Nasdaq: COO) has announced it will release its first quarter 2025 financial results on Thursday, March 6, 2025, at 4:15 PM ET. The company will host a conference call at 5:00 PM ET on the same day to discuss the results and current corporate developments. Investors can join the call using the dial-in number 800-715-9871 with conference ID 7466264. An audio webcast and replay will be available on the company's investor relations website.

CooperCompanies (NYSE: COO), a prominent medical device company, has announced its participation in the upcoming J.P. Morgan Healthcare Conference. The company's presentation is scheduled for Tuesday, January 14, 2025, at 6:00 PM ET. Al White, President and CEO, will be representing CooperCompanies at the conference. Interested parties can access both live and archived webcasts of the presentation through the company's investor relations website at http://investor.coopercos.com.

CooperCompanies (COO) reported strong financial results for Q4 and full year 2024. Q4 revenue reached $1,018.4 million, up 10% (7% organically), while fiscal year 2024 revenue hit $3.9 billion, up 8% organically. Q4 GAAP EPS increased 38% to $0.58, and non-GAAP EPS rose 19% to $1.04.

The company achieved record consolidated revenues, with strong performance in both CooperVision and CooperSurgical divisions. Q4 gross margin improved to 67% from 65% last year, while operating margin increased to 19% from 15%. For fiscal 2025, Cooper projects revenue of $4.08-4.16 billion with organic growth of 6-8%, and non-GAAP EPS guidance of $3.92-4.02.

CooperCompanies (Nasdaq: COO) has scheduled its fourth quarter and full year 2024 financial results announcement for Thursday, December 5, 2024, at 4:15 PM ET. The company will hold a conference call at 5:00 PM ET to discuss results and corporate developments. Interested parties can join via phone at 800-715-9871 using conference ID 2026064, or access the audio webcast through the investor relations website.

The Canadian Association of Optometrists (CAO) has launched a national campaign for Children Vision Month in October to raise awareness about myopia and the importance of annual eye exams for children. Myopia, affecting 30% of the population, is expected to increase to 50% by 2050. The campaign, supported by provincial optometrist associations and industry sponsors, aims to debunk myths and encourage early detection.

Key points:

• Myopia is a leading cause of vision loss globally
• Increased screen time is correlated with higher rates of myopia in children
• CAO recommends annual eye exams for children from 6-9 months to 19 years old
• Outdoor time may help delay myopia onset
• Limiting screen time and taking regular breaks are recommended

The campaign will run on various social media platforms throughout October, providing resources for parents to find local optometrists and take proactive steps for their children's eye health.

CooperCompanies (Nasdaq: COO) has been recognized as a Best Workplace for Innovators by Fast Company, highlighting its commitment to fostering innovation and employee development. The company's culture inspires the creation of new products and advocacy initiatives aimed at improving standard-of-care in the medical device industry.

Key points:

• CooperCompanies is a leading global medical device company
• The award recognizes organizations worldwide that encourage innovation at all levels
• CEO Al White emphasized the company's significant investments in people and innovation
• CooperCompanies also received recognition on the 2024 Top 100 Inspiring Workplaces in North America list
• The company achieved a perfect score of 100 on the Human Rights Campaign's Corporate Equality Index

CooperSurgical has launched a new single-hand inserter for its Paragard® Intrauterine Copper Contraceptive, recently approved by the FDA. This innovation simplifies the placement process for healthcare providers, making Paragard more accessible. Paragard, the #1 prescribed copper IUD, offers over 99% efficacy for up to 10 years and is hormone-free.

Key features of Paragard include:

• Immediate reversibility
• 30+ years of clinical use
• 91% satisfaction rate among users aged 25-50 after at least one year
• New inserter with built-in loading tip and single-hand functionality

The launch aligns with CooperSurgical's mission to deliver innovative solutions for patients and providers in women's healthcare.

CooperCompanies (Nasdaq: COO) reported strong Q3 2024 results with revenue up 8% year-over-year to $1,002.8 million. CooperVision revenue increased 7% to $675.6 million, while CooperSurgical revenue grew 9% to $327.2 million. GAAP diluted EPS rose 22% to $0.52, and non-GAAP diluted EPS increased 14% to $0.96. The company raised its fiscal year 2024 guidance, projecting total revenue of $3,892 - $3,913 million (8-8.5% organic growth) and non-GAAP diluted EPS of $3.64 - $3.67. Strong performance was attributed to successful execution of growth strategies and operational efficiency.